Qinhuang Oral Solution Veterinary Grade API is received as a pharmaceutical intermediate for conversion into non-sterile and sterile veterinary dosage forms. The certificate of analysis documents residual solvents under VICH GL18, related substances under VICH GL8, and the microbiological examination of non-sterile substances under Ph. Eur. 5.1.4. Moisture content is controlled below 0.5% w/w for solid-dose processing unless otherwise justified by stability data. Material is weighed and dispensed in dedicated pharmaceutical suites with charge-in verification per 21 CFR 211.101. The following application tracks cover direct compression, capsule filling, aqueous injection, feed premix, wet granulation, drinking water medication, and soluble powder conversion.

Direct Compression of Veterinary Oral Tablets with Low-Moisture Excipient Systems

Direct compression is selected when the active substance exhibits adequate flowability after blending with spray-dried lactose monohydrate and microcrystalline cellulose. A starting formula is prepared at 5.0 wt% active loading in a 500 mg target tablet weight. The dry blend is mixed in a twin-shell blender at 60% fill ratio for 20 min at 15 rpm, screened through an 850 µm mesh, and lubricated with 0.5 wt% sodium stearyl fumarate. Magnesium stearate is not used when dissolution retardation is critical. Powder flow is measured by ring shear cell per ASTM D6773-16; a flow function coefficient of 4.0–6.0 is targeted. Compression is performed on a rotary tablet press with 10 mm round flat-faced tooling. Compression force is maintained between 10 kN and 18 kN to produce tablet breaking force from 60 N to 100 N under Ph. Eur. 2.9.8. Tablet mass uniformity is monitored in-process at 10 min intervals against Ph. Eur. 2.9.5. Disintegration time is evaluated in water at 37 °C using Ph. Eur. 2.9.1 apparatus. The compressed tablets are intended for oral administration to dogs and cats in body-weight-adjusted doses. Terminal product release includes assay, related substances, moisture, and dissolution using USP <711> apparatus 2 at 50 rpm.

Low ambient humidity is required during direct compression. When relative humidity exceeds 60% RH, the lactose-based blend is pre-dried in a fluid-bed dryer at 40 °C until loss on drying reaches ≤ 0.5% w/w. The API-containing blend is not stored for more than 24 h after lubrication because sodium stearyl fumarate can redistribute under extended hopper residence times. Tablet weight target is adjusted according to the labelled claim; small-sized tablets for companion animals are compressed at 2.0 wt% to 5.0 wt% active loading. The process is validated across 3 consecutive batches with blend uniformity sampling at 10 points per blender. Acceptance criteria for blend content uniformity are RSD ≤ 5.0% and individual values within 90.0%–110.0% of labelled claim. Hopper vibration is avoided on the tablet press because particle segregation increases when vibration amplitude exceeds 0.5 mm. Tablets are dedusted and metal-checked with a 2.0 mm ferrous, non-ferrous, and stainless-steel detector sensitivity. Embossed tooling is employed only with emboss depth below 0.2 mm to prevent capping. Core tablets are stored in PVC/PVDC/aluminium blisters with a water vapor transmission rate ≤ 0.20 g/m²/day at 38 °C/90% RH. Blister seal integrity is tested with vacuum decay at -0.25 bar for 30 s. Tablets with moisture uptake above 0.8% w/w after 24 h open-bowl exposure are rejected from stability feed.

Size 3 hard gelatin capsule operations encounter fewer dust-induced segregation risks when the active substance is pre-dispersed in a 1:9 mass ratio with milled lactose monohydrate before final blending. The triturate is prepared by geometric dilution in a high-shear mixer at 150 rpm for 5 min, then passed through a 500 µm conical mill. The final blend is brought to 100% with pregelatinized starch and microcrystalline cellulose. Capsule filling is carried out on a dosator-type automatic encapsulation machine with target fill weight set from 0.250 g to 0.500 g per capsule. Fill weight variation is controlled in-process using Ph. Eur. 2.9.5. Dissolution testing uses USP <711> apparatus 1 at 100 rpm with 0.1 M hydrochloric acid medium at 37 °C. The terminal product is a hard gelatin capsule for oral administration to cattle or swine after feed withdrawal. A preservative is not required in this solid dosage form. The filled capsules are stored in HDPE containers with silica gel desiccant. Release testing includes microbial limits according to Ph. Eur. 5.1.4 because the product is non-sterile. Batch-to-batch variance in powder flow is managed by adjusting the pregelatinized starch content between 5.0 wt% and 15.0 wt%. When the capsule fill weight falls below 0.300 g, an overhead compaction step is avoided due to the risk of plug formation in size 3 bodies.

For moisture-protective packaging, the capsule product is sealed with a 35 mm film-backed lidding foil after filling. Active substance particle size distribution is monitored with laser diffraction; D₉₀ is held below 250 µm for acceptable blend homogeneity. If the particle size exceeds this threshold, the material is re-milled using a 0.5 mm screen fitted to a cone mill and blended for an additional 10 min. In-process assay is sampled at 5 points across the hopper and 5 points across the discharge stream. The acceptance criterion is RSD ≤ 5.0%. Dosing disc height and tamping pin depth are set to compact the powder to plug density 0.75–0.85 g/mL before ejection into the capsule body. Capsule lock length is inspected by vision system with a tolerance of ± 0.2 mm. The desiccant content is calculated from the shell moisture sorption isotherm. The bottle closure is torqued to 25 N·cm for polypropylene closures with induction seal.

What Terminal Sterilization Pathway Is Validated for Aqueous Veterinary Injectables?

Injectable conversion is performed only when a parenteral-grade aqueous vehicle can maintain the active substance in solution without precipitation. The vehicle is prepared with water for injection, 0.9% w/v sodium chloride, and a citrate buffer adjusted to pH 5.5. The API is added at a target concentration of 10 mg/mL for large-animal formulations. The bulk solution is filtered through a 0.45 µm clarifying filter followed by a 0.22 µm PVDF sterilizing-grade filter. The filtered bulk solution exhibits viscosity between 1.0 mPa·s and 1.3 mPa·s at 25 °C. Filling is conducted in a Grade A unidirectional airflow zone within Grade C background using USP Type I borosilicate glass vials. Filling speed is adjusted to avoid foam; a maximum line speed of 150 vials/min applies for 100 mL vials. Terminal sterilization is selected only if the API demonstrates acceptable thermal recovery in a forced degradation study at 121 °C. When terminal moist-heat sterilization is validated, the cycle is run at 121 °C for 15 min with F₀ ≥ 12 min. Chamber pressure is counterbalanced at 2.0–2.5 bar to prevent closure movement. Temperature mapping verifies the cold spot reaches 121 °C for at least 15 min. The load is cooled to below 40 °C before unloading. Sterility assurance follows Ph. Eur. 5.1.1. Bacterial endotoxin limits are tested per Ph. Eur. 2.6.14 and calculated from the maximum dose and route. The terminal product is a clear aqueous injection for intramuscular or subcutaneous administration in cattle, sheep, or pigs.

For heat-labile batches, filtration followed by aseptic filling under Grade A is used instead of terminal sterilization. In that case, pre-sterilization of the vehicle is performed at 121 °C for 15 min. Container-closure integrity is verified by dye ingress or vacuum decay. The injection is not formulated with antimicrobial preservatives when the vial size is a single-dose presentation. For multi-dose vials, preservative efficacy testing under Ph. Eur. 5.1.3 is required. The API concentration is adjusted based on species-specific pharmacokinetic data; no default ratio applies across species. The manufacturing instruction requires pH check before and after addition of the API because pH drift can alter solubility. Published data for the thermal degradation kinetics of this specific configuration is limited; a forced decomposition study at 121 °C is therefore required for each new batch family and container-closure configuration.

Holding time between bulk solution preparation and filtration is limited to 4 h at room temperature unless the solution is stored under 2–8 °C. Under validated cold storage, the maximum holding time is 24 h. Terminal sterilized batches require sterile filter integrity testing by bubble point or diffusive flow. The vial washer uses 70 °C final rinse water with conductivity below 1.0 µS/cm. Depyrogenation is performed in a dry-heat tunnel at 250 °C for 45 min. Terminal sterilizer validation includes heat penetration studies in the largest and smallest vial. The temperature difference between chamber and vial cold spot is maintained at ≤ 1.5 °C. Biological indicators with Geobacillus stearothermophilus spores are placed in the cold spots. The target spore log reduction is ≥ 6.

When the API Is Incorporated into Feed Premix Carriers for Swine and Poultry

In-feed medication is prepared by first adsorbing the active substance onto precipitated silica dioxide at a ratio of 1.0 kg active to 0.5 kg silica dioxide. The loaded silica is blended with ground limestone and wheat middlings as carrier. The premix is prepared at a concentration of 10.0% w/w active substance. Mixing is performed in a horizontal ribbon blender with a working capacity of 500 kg for 15 min. The blended premix is discharged into 25 kg paper-lined HDPE bags. Homogeneity testing follows Commission Regulation (EC) No 152/2009 with 10 sampling points per batch. The acceptance criterion for active substance content uniformity is CV ≤ 5.0%. The premix is further diluted on farm at 1–5 kg per tonne of complete feed according to the prescribed daily dose. Carryover control is validated by flushing the ribbon blender with 50 kg of carrier after each API batch. The flush material is either discarded or used as a subsequent carrier component. The terminal product is medicated feed for swine and poultry.

Dust generation is monitored at the bagging station with a real-time aerosol photometer. Operators use NIOSH-certified respirators when the containment risk exceeds 0.1 mg/m³ airborne dust. The API-loaded silica is not combined with mineral oil because oil-coated carriers can reduce active release in feed assays. The premix release specification includes loss on drying ≤ 5.0% w/w, particle size through a 2.0 mm screen, and total aerobic microbial count ≤ 10,000 CFU/g per Ph. Eur. 5.1.4. The premix is not mixed with ionophore coccidiostats during the same production campaign unless validated cleaning prevents carryover below 0.1% of the lowest therapeutic dose. Dedicated scoops and sampling tools are color-coded.

Ribbon blender tip speed is maintained at 0.8 m/s to minimize fines generation. The relative standard deviation of active content after 15 min is ≤ 5.0%. When CV exceeds 5.0%, mixing is extended in 5 min increments to a maximum of 30 min; beyond 30 min, demixing occurs due to particle size and density differences. The premix is not conveyed by pneumatic transfer after final blending because segregation potential increases. The product is sampled at the point of bagging, not from the blender discharge, to reflect the worst-case segregation state. Particle size distribution of the final premix is measured by sieve analysis with 0.25 mm, 0.5 mm, 1.0 mm, and 2.0 mm meshes. The mass fraction on the 1.0 mm sieve is controlled at 20%–40% to balance dust reduction and mixing efficiency.

Wet granulation converts the low-bulk-density powder fraction into free-flowing, dust-reduced granule intermediate for sachet filling. The active substance is mixed with lactose monohydrate and maize starch in a high-shear granulator. The binder is purified water containing 5.0% w/w povidone K30. Binder solution is added at a rate of 0.5 kg/min until the granulation endpoint is confirmed by main motor current increase of 10%–15% over dry-mix baseline. Wet mass is passed through a 2.0 mm sieve and dried in a fluid-bed dryer at inlet air temperature 65 °C. Product temperature is maintained below 40 °C. Drying continues until loss on drying is 1.0%–2.0% w/w. The dried granules are sized through a 1.0 mm oscillating granulator. The terminal product is packed as 10 g or 100 g sachets for oral administration to pigs and calves. The granule product is reconstituted with drinking water before dosing. Disintegration is not applicable to this dispersible granule presentation. Instead, dispersion quality is tested by adding 10 g granules to 1 L water at 25 °C and swirling for 2 min. The resulting dispersion must pass through a 0.5 mm sieve without retained particles.

Granule size distribution is measured by sieve analysis using 355 µm, 500 µm, 710 µm, and 1.0 mm meshes. The fraction retained between 500 µm and 710 µm is controlled at 40%–60% of total mass. If granules are below 355 µm, dusting occurs during sacheting; if above 1.0 mm, reconstitution time increases. The sachet line uses vertical form-fill-seal equipment with a 60 mm film width. Seal integrity is tested per ASTM F88/F88M-21 with a minimum seal strength of 0.60 N/mm. Granulator main motor current is recorded continuously. A torque plateau or decrease without continued binder addition indicates over-granulation. Wet mass bulk density is checked by weighing 1 L of wet granulate; the target is 0.55–0.65 g/mL. Fluid-bed product temperature is used to adjust inlet air dew point. If the product temperature exceeds 40 °C, the inlet air temperature is reduced in 5 °C steps until the exhaust air relative humidity falls below 20%.

Granules are not stored in unlined stainless steel bins for more than 72 h without moisture barrier wrapping. The final sachets are placed in aluminum pouches with desiccant. The release test includes loss on drying, sieve analysis, active content, and microbial quality under Ph. Eur. 5.1.4. Flowability is evaluated per Ph. Eur. 2.9.36; a compressibility index ≤ 25% and Hausner ratio ≤ 1.25 are targeted for sachet machine feeding.

Drinking Water Medication pH Control and Proportioner Accuracy

Oral solution preparation for flock drinking water requires a buffered aqueous vehicle that resists pH shift in hard water. The API is dissolved in purified water with citric acid and sodium citrate dihydrate to achieve pH 5.5–6.0. A representative stock solution is prepared at 20 mg/mL active content and administered through a 1:100 dosing pump to yield 0.20 mg/mL in the final drinking water line. The stock solution is packaged in 1 L HDPE bottles with UV-resistant overpouches. The solution is protected from direct sunlight during storage. Stability evaluation follows VICH GL3 with samples stored in the intended commercial container. The formulation includes 0.05% w/w sodium metabisulfite as antioxidant. In hard water containing 300 mg/L calcium carbonate equivalent, no visible precipitate forms after 24 h at 25 °C. Microbiological quality of the non-sterile oral solution is tested under Ph. Eur. 5.1.4. The acceptance criteria are total aerobic microbial count ≤ 100 CFU/mL and total combined yeasts and moulds ≤ 10 CFU/mL. The terminal product is a drinking water medication for poultry and swine.

The dosing pump is calibrated daily with a graduated cylinder. Proportioner variation must not exceed ±5.0% of the target volume. Diaphragm wear is monitored after 1000 L of stock solution. The stock solution is not overdiluted below 2 mg/mL because microbial proliferation risk increases in dilute non-preserved liquids. Packaged solution is not stored above 30 °C. Stability samples are stored at 25 °C/60% RH and 40 °C/75% RH. Assay, pH, clarity, and microbial limits are determined at 0, 3, 6, 12, and 24 months. A measurable pH drift greater than 0.5 units or assay loss of 5.0% triggers a formulation redevelopment. The product is not mixed with acidified feed additives containing high chloride ion concentrations because precipitation has been observed in development batches at chloride concentrations above 2000 mg/L.

Water line material compatibility is evaluated before field use. The buffered solution is circulated through PVC and stainless-steel drinking lines for 72 h at 25 °C. Weight loss, swelling, and visual changes are recorded. Particle formation is monitored by turbidity at 425 nm; the limit is ≤ 10 NTU. If the stock solution is supplied in bulk 200 L drums, a vent filter is used during dispensing to reduce microbial ingress. Dispensing valves are disinfected daily with 70% isopropanol followed by purified water rinse.

For flock-level oral administration through closed water lines, a soluble powder format is selected when the active substance demonstrates sufficient aqueous solubility after wetting. The powder is prepared by blending the API with anhydrous citric acid, sodium bicarbonate, lactose monohydrate, and sodium lauryl sulfate in a sachet line. A representative batch contains 5.0% w/w active substance, 10.0% w/w citric acid, 8.0% w/w sodium bicarbonate, and 77.0% w/w lactose monohydrate. The blend is mixed in a double-cone blender at 15 rpm for 20 min. Powder fill weight is controlled to ±3.0% of target. The terminal product is a 500 g pouch for reconstitution in 250 L drinking water. Dissolution is confirmed by adding 10 g powder to 1 L water at 25 °C. The solution becomes clear within 3 min under gentle stirring. Insoluble residue is tested by filtration through a 0.355 mm sieve. Effervescent aids in this formulation are not present at higher levels because gas evolution can cause feeding-line air locks in closed systems.

Effervescent powder presentations are packed in foil laminate with a moisture vapor transmission rate below 0.05 g/m²/day at 38 °C/90% RH. The sachet seal is inspected for pinholes using vacuum leak detection. The powder is not recommended for use in water containing iron above 1.0 mg/L because iron complexation may reduce soluble active concentration. Batch release includes assay, loss on drying ≤ 1.0% w/w, sieve analysis, and microbial quality per Ph. Eur. 5.1.4. Powder angle of repose is measured according to Ph. Eur. 2.9.36; the target is ≤ 40°. Compressibility index is controlled at ≤ 25%.

Reconstituted solution hold time is limited to 12 h at 25 °C. After 12 h, the solution is discarded because microbiological growth in non-preserved potable water can exceed the non-sterile limit. The preparation area uses ≤ 40% RH to prevent premature effervescent reaction. Batch size is capped by the double-cone blender working volume at 60% fill. Blender discharge is sampled at 5 points per batch for blend uniformity with acceptance RSD ≤ 5.0%. Sachet labeling includes a species-specific dosing table and withdrawal period text as required by the competent regulatory authority.